摘要
艾曲波帕作为一种人体血小板生成素受体激动剂，用于治疗血小板减少和重型再生障碍性贫血，近年其在去铁方面突显出巨大优势，它通过调节体内葡萄糖醛酸化代谢，在机体内的铁与肝脏共轭之前将其从粪便和尿液中排除，从而有效降低人体内的过载铁。
Eltrombopag is a kind of human thrombopoietin receptor agonist, which is used to treat thrombocytopenia and severe aplastic anemia. In recent years, it highlights the huge advantage in iron removal. It regulates the acidification of glucuronidation in the body, removing it from feces and urine before iron conjugates to the liver, so as to effectively reduce the overload of iron in the body.
作者
毛东锋
吴涛
曹红刚
白海
Mao Dongfeng, Wu Tao, Cao Honggang, Bai Hai(Department of Hematology, Lanzhou General Hospital, Lanzhou Command, Lanzhou 730050, China)
出处
《中国医师进修杂志》
2018年第11期1046-1048,共3页
Chinese Journal of Postgraduates of Medicine
基金
甘肃省自然科学基金资助（145RJZA151）
关键词
铁代谢障碍
受体
血小板生成素
综述
艾曲波帕
Iron metabolism disorders
Receptors
thrombopoietin
Review
Ehrombopag
